Clinical Cancer Research  Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, J.-H.
Right arrow Articles by Bang, Y.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, J.-H.
Right arrow Articles by Bang, Y.-J.
Clinical Cancer Research Vol. 10, 5271-5281, August 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation

Jung-Hyun Park1,2, Yeonjoo Jung1,2, Tai Young Kim1,2, Sang Gyun Kim1, Hyun-Soon Jong1,2, Jung Weon Lee1,2, Dae-Kee Kim4, Jong-Soo Lee5, Noe Kyeong Kim3, Tae-You Kim1,2,3 and Yung-Jue Bang1,2,3

1 National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, 2 Department of Tumor Biology, and 3 Department of Internal Medicine, Seoul National University College of Medicine, Seoul; 4 In2Gen Co., Ltd., Seoul; and 5 Carcinogenesis Branch, Division of Basic Sciences, National Cancer Center Research Institute, Ilsan, Korea

We have developed previously a class of synthetic hybrid histone deacetylase (HDAC) inhibitors, which were built from hydroxamic acid of trichostatin A and pyridyl ring of MS-275. In this study we evaluated the antitumor effects of these novel hybrid synthetic HDAC inhibitors, SK-7041 and SK-7068, on human cancer cells. Both SK-7041 and SK-7068 effectively inhibited cellular HDAC activity at nanomolar concentrations and induced the time-dependent hyperacetylation of histones H3 and H4. These HDAC inhibitors preferentially inhibited the enzymatic activities of HDAC1 and HDAC2, as compared with the other HDAC isotypes, indicating that class I HDAC is the major target of SK-7041 and SK-7068. We found that these compounds exhibited potent antiproliferative activity against various human cancer cells in vitro. Growth inhibition effect of SK-7041 and SK-7068 was related with the induction of aberrant mitosis and apoptosis in human gastric cancer cells. Both compounds induced the accumulation of cells at mitosis after 6 h of treatment, which was demonstrated by accumulation of tetraploid cells, lack of G2 cyclin/cyclin-dependent kinase inactivation, and higher mitotic index. After 12 h of treatment, apoptotic cells were increased through mitochondrial and caspase-mediated pathway. Finally, in vivo experiment showed that SK-7041 or SK-7068 was found to reduce the growth of implanted human tumors in nude mice. Therefore, based on isotype specificity and antitumor activity, SK-7041 and SK-7068 HDAC inhibitors are expected to be promising anticancer therapeutic agents and need additional clinical development.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. Liu, H. Cheng, W. Kwan, J. M. Lubieniecka, and T. O. Nielsen
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
Mol. Cancer Ther., June 1, 2008; 7(6): 1751 - 1761.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Wang, S. A. Mahmud, P. B. Bitterman, Y. Huo, and A. Slungaard
Histone Deacetylase Inhibitors Suppress TF-{kappa}B-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes
J. Biol. Chem., September 28, 2007; 282(39): 28408 - 28418.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T.-M. Lee, M.-S. Lin, and N.-C. Chang
Inhibition of histone deacetylase on ventricular remodeling in infarcted rats
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H968 - H977.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
Y.-B. Kim, S.-Y. Lee, S.-K. Ye, and J. W. Lee
Epigenetic regulation of integrin-linked kinase expression depending on adhesion of gastric carcinoma cells
Am J Physiol Cell Physiol, February 1, 2007; 292(2): C857 - C866.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. A. Kim, J. H. Shin, I. H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E. K. Chie, S. W. Ha, C. I. Park, and G. D. Kao
Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53
Clin. Cancer Res., February 1, 2006; 12(3): 940 - 949.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. J. Kee, I. S. Sohn, K. I. Nam, J. E. Park, Y. R. Qian, Z. Yin, Y. Ahn, M. H. Jeong, Y.-J. Bang, N. Kim, et al.
Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding
Circulation, January 3, 2006; 113(1): 51 - 59.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
S. G. Kim, H.-A. Kim, H.-S. Jong, J.-H. Park, N. K. Kim, S. H. Hong, T.-Y. Kim, and Y.-J. Bang
The Endogenous Ratio of Smad2 and Smad3 Influences the Cytostatic Function of Smad3
Mol. Biol. Cell, October 1, 2005; 16(10): 4672 - 4683.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. J. Barnes, I. M. Adcock, and K. Ito
Histone acetylation and deacetylation: importance in inflammatory lung diseases
Eur. Respir. J., March 1, 2005; 25(3): 552 - 563.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.